Financial health
- Operating income covered interest expense -957.3× in the latest year.
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
14 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2026 | $131000 | -$14M | 100.0% | -8768.7% | 1259.6% | -187.4% | -$11M | — | $5M |
| 2025 | $144000 | -$2M | 96.5% | -8761.1% | -23.7% | -17.0% | -$9M | — | $11M |
| 2024 | $109000 | -$15M | 0.0% | -13840.4% | -407.4% | -231.1% | -$15M | — | $3M |
| 2023 | $370000 | -$17M | 0.0% | -4792.2% | -112.6% | -85.0% | -$13M | — | $15M |
| 2022 | $2M | -$11M | 0.0% | -765.3% | -37.9% | -34.4% | -$9M | — | $29M |
| 2021 | $0 | -$17M | — | — | -42.9% | -42.2% | -$14M | — | $37M |
| 2020 | $2M | -$19M | 85.1% | -977.9% | -70.3% | -65.8% | -$15M | — | $27M |
| 2019 | $3M | -$27M | 84.4% | -882.4% | -73.4% | -65.6% | -$20M | — | $36M |
| 2018 | $5M | -$35M | 77.6% | -766.3% | -78.1% | -69.8% | -$29M | — | $44M |
| 2017 | — | -$38M | — | — | -61.7% | -55.6% | — | — | $63M |
| 2016 | — | -$39M | — | — | -62.0% | -57.1% | — | — | $62M |
| 2015 | — | -$30M | — | — | -61.8% | -56.2% | — | — | $50M |
| 2014 | — | -$26M | — | — | -53.5% | -51.5% | -$16M | — | $48M |
| 2012 | — | -$44M | — | — | 821.3% | -260.0% | -$10M | — | $15M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $18000 | -$1M | 0.0% | -15327.8% | 57.0% | -34.8% | -$3M | — | $2M |
| Dec '25 | $26000 | -$3M | 100.0% | -10576.9% | -60.6% | -38.7% | -$2M | — | $4M |
| Sep '25 | $28000 | -$3M | 100.0% | -9410.7% | -36.0% | -26.3% | — | — | $7M |
| Jun '25 | $37000 | -$3M | 100.0% | -7878.4% | -29.8% | -23.7% | -$4M | — | $9M |
| Mar '25 | $51000 | $7M | 100.0% | -6184.3% | 65.3% | 46.8% | -$2M | — | $11M |
| Dec '24 | $24000 | -$3M | 91.7% | -14450.0% | -947.0% | -89.7% | -$2M | — | $1M |
| Sep '24 | $30000 | -$3M | 96.7% | -8693.3% | -69.3% | -37.7% | -$3M | — | $3M |
| Jun '24 | $39000 | -$3M | 94.9% | -8682.1% | -50.2% | -35.3% | -$3M | — | $6M |
| Mar '24 | $29000 | -$3M | 0.0% | -10675.9% | -84.6% | -48.0% | -$3M | — | $3M |
| Dec '23 | $5000 | -$4M | 100.0% | -73600.0% | -58.3% | -40.6% | -$4M | — | $5M |
| Sep '23 | $0 | -$4M | — | — | -47.2% | -35.8% | -$3M | — | $8M |
| Jun '23 | $75000 | -$4M | 100.0% | -5593.3% | -34.2% | -27.3% | -$5M | — | $11M |
| Mar '23 | $162000 | -$7M | 0.0% | -4801.9% | -48.7% | -36.7% | -$5M | — | $15M |
| Dec '22 | $131000 | -$3M | 0.0% | -2564.1% | -14.6% | -13.0% | -$3M | — | $20M |
| Sep '22 | $77000 | -$3M | 0.0% | -4355.8% | -13.3% | -11.9% | -$2M | — | $13M |
| Jun '22 | $0 | -$3M | — | — | -11.6% | -10.5% | -$2M | — | $16M |
| Mar '22 | $2M | -$2M | 0.0% | -127.5% | -6.3% | -5.7% | -$2M | — | $29M |
| Dec '21 | $0 | -$4M | — | — | -11.2% | -10.0% | -$3M | — | $30M |
| Sep '21 | $0 | -$4M | — | — | -10.2% | -9.8% | -$2M | — | $34M |
| Jun '21 | — | -$3M | — | — | -6.8% | -6.6% | -$2M | — | $36M |
How the market has priced VIVS against its own fundamentals since 2025-04 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
See the revenue and net-income charts above for VivoSim Labs, INC.'s multi-year trend.
As of FY2026, VivoSim Labs, INC. reported — of total debt against $5M of cash; operating income covered interest expense -957.3×.
In FY2026, gross margin was 100.0%, operating margin -8768.7%, and net margin -10567.2%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.